Navigation Links
Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
Date:1/3/2008

KENILWORTH, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its Board had elected Dr. Craig B. Thompson as a member of its Board of Directors, effective Jan. 2, 2008. Dr. Thompson is Director of the Abramson Cancer Center and Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia.

Dr. Thompson is an independent director under both the New York Stock Exchange standards and the more restrictive Schering-Plough Board independence standards.

Dr. Thompson, 54, earned an M.D. from the University of Pennsylvania School of Medicine and an AB from Dartmouth College. He chairs the Medical Advisory Board at the Howard Hughes Medical Institute, serves on the advisory boards of St. Jude Children's Research Hospital and M.D. Anderson Cancer Center, and participates in a number of other professional and civic activities.

"Craig's perspective as a scientist and physician will add significant strength to our work as a Board," said Patricia F. Russo, Chair of the Board's Nominating and Corporate Governance Committee. "We are pleased to continue to increase the collective knowledge of the Board with this new member."

"Craig brings deep experience to our Board in the fields of medicine, medical research and fighting cancer, an important priority for humankind. This additional strength on the Board is critical as we continue to increase Schering-Plough's science-focus during our progression along our Action Agenda to transform Schering-Plough into a high-performance, global competitor for the long term," said Fred Hassan, Schering-Plough chairman and chief executive officer.

Schering-Plough is an innovation-driven, science-centered global
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
3. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
4. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
7. Schering-Plough Reports Financial Results for Third Quarter of 2007
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Louise McCormick Joins Heskas Board of Directors
11. Combined Boards Provide Better Care to More Clients More Efficiently
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
... study it is shown that people with autism may suf...ponsible for handling spatial memory. Studies on a...ate// deficits in higher-order thinking abilities,...g memory, and voluntary response inhibition. These...
...ers at the Mayo Clinic, the present risk of progno...of more factors if they are to be useful in assess...a heart attack or is at risk of having one what th...ht hold. Doctors can use the prediction tools and ...
...red light may enable assessment of blood chemistry...as many potential spin-offs for health on the grou... Space Biomedical Research Institute, is needle-fr...ake blood samples in space, for medical research. ...
...archers, points to the importance of cancer patien...ressed feelings. Researchers feel that with a firm...th them, //the patient is left with increased feel...chers from the University of Texas performed a uni...
Other Medicine News:
(Date:10/13/2008)... from Multiple Cancer Populations Facilitates ..., Mich., Oct. 13 /- Rubicon Genomics,...rick to amplify DNA samples for The,Cancer Atlas G...amplify and standardize total genomic,DNA from 3,0...The Rubicon,GenomePlex(TM) Whole Genome Amplificat...
(Date:10/10/2008)...RK, Calif., Oct. 10 /-,XTEN...lans to present,long-term follow-up data from the ...the Cardiovascular Research Foundation,s (CRF) twe...utics (TCT) meeting in Washington, DC.,The CUSTOM ...o investigate,the safety and efficacy of the Custo...
(Date:10/10/2008).... 10 /- TriReme Medical Inc. (TMI),an... the CE (Conformite,Europeenne) marking and commer...ystem, a unique main vessel stent system specially...., Representing the next generation in bifurcatio...se in a quarter of the 2.2 million,angioplasty pro...
(Date:10/9/2008)...cience Institute, Navigenics, Affymetrix and,Micro...GO, Oct. 9 /- A consortium of health ...forces in a first-of-its-kind,research study to as...ting,on people who choose to receive such screenin... certain diseases., Sponsored by Scripps Translat...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Simvastatin Leads Pfizers Lipitor in Second Line Patient Share for the Treatment of Dyslipidemia 19176 1Simvastatin Leads Pfizers Lipitor in Second Line Patient Share for the Treatment of Dyslipidemia 19176 2Simvastatin Leads Pfizers Lipitor in Second Line Patient Share for the Treatment of Dyslipidemia 19176 3Medifast Inc Names Barry B Bondroff CPA to Board of Directors 19174 1Medifast Inc Names Barry B Bondroff CPA to Board of Directors 19174 2CEOs From Multiple Health Industries Announce Consensus Plan to Reform U S Health Care 19172 1CEOs From Multiple Health Industries Announce Consensus Plan to Reform U S Health Care 19172 2CEOs From Multiple Health Industries Announce Consensus Plan to Reform U S Health Care 19172 3Why Our Kids Cant Breathe in Our Communities 19169 1Why Our Kids Cant Breathe in Our Communities 19169 2Why Our Kids Cant Breathe in Our Communities 19169 3
...Mullerian Inhibiting Substance (MIS), also known a...glycoprotein dimer composed of two 72 kDa monomers...to the transforming growth factor-? (TGF-?) superf... and activin glycoproteins (2). All members of thi...
The STA Compact CT is a completely automated, benchtop hemostasis analyzer capable of performing clotting assays in random access mode. The system's unique method of sample management offers high thr
...Alpha Fetoprotein (AFP) is a 68 kDa protein, which...tal liver and yolk sac [1]. Human fetal serum AFP...n rates reach 19-26 g/min during mid-gestation (14...es of total fetal AFP continue to increase after m...
Compensating for movement is critical to weighing patients in wheelchairs. Thats why this scale has the exclusive technology to do just that. Extremely durable, with state-of-the-art technology, thes
Medicine Products: